Participants 48 100 7
patients with type 2 diabetes in the PROactive Study
Participants 211 240 7
Patients with type 2 diabetes
Participants 570 609 6
high-risk patients with type 2 diabetes
Participants 672 748 5
5238 patients with type 2 diabetes who had evidence of macrovascular disease
Participants 763 813 3
patients from primary-care practices and hospitals
Participants 1549 1620 4
514 of 2605 patients in the pioglitazone group and 572 of 2633 patients
Participants 1852 1864 3
301 patients
Participants 1895 1919 3
358 in the placebo group
Participants 2410 2484 6
patients with type 2 diabetes who have a high risk of macrovascular events
